On May 16, 2022 ​Imago BioSciences, Inc. ("Imago") (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs), reported that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in three upcoming investor conferences (Press release, Imago BioSciences, MAY 16, 2022, View Source [SID1234614665]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

HC Wainwright Global Investment Conference. Dr. Rienhoff will participate in a virtual presentation that will be available on demand beginning on Tuesday, May 24, 2022 at 7:00 am ET.

Cowen Oncology Innovation Summit. Dr. Rienhoff will present in an analyst led fireside chat on Thursday, June 2, 2022 at 3:00 pm ET.

Jefferies Healthcare Conference. Dr. Rienhoff will present on Wednesday, June 8, 2022 at 9:30 am ET.

Interested parties can access the live webcasts for these conferences from the Investor Relations section of the company’s website at www.imagobio.com. The webcast replays will be available after the conclusion of each conference.

On May 16, 2022 Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported that members of the Company’s management team will participate at the following investor conferences in May 2022 (Press release, Altimmune, MAY 16, 2022, View Source [SID1234614664]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Global Investment Conference
Tuesday, May 24, 2022
7:00 am Eastern Time
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
B. Riley Securities Institutional Investor Conference
Thursday, May 26, 2022
1:00 pm Pacific Time
The session will be an in person fireside chat.

On May 16, 2022 Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, reported that it will report financial results for its fiscal fourth quarter and year ended March 31, 2022 on Thursday, June 16, 2022 (Press release, Beyond Air, MAY 16, 2022, View Source [SID1234614663]). The Company’s management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On May 16, 2022 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported new preclinical data showing that silencing BRD4 with PH-894, a self-delivering RNAi INTASYL compound, can be used to improve the characteristics of CAR-T cell products during the activation and expansion phases of the cell manufacturing process (Press release, Phio Pharmaceuticals, MAY 16, 2022, View Source [SID1234614662]). These new data will be presented at the American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 25th Annual Meeting, which is being held in Washington D.C., from May 16-19, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Hurdles that are faced with current CAR T-cell therapy treatment for solid tumors include cell persistence and cell exhaustion. Due to the immunosuppressive environment of the tumor, CAR T-cells may become exhausted, thereby limiting the efficacy of treatment for cancer patients," said Dr. Simon Fricker, Phio’s VP of Research and Development. "These data demonstrate that PH-894 could enhance the activity of CAR-T cells by improving the quality of the final CAR-T cell product by overcoming immunosuppression, reversing exhaustion, and preserving a phenotype associated with cell persistence. There is potential for PH-894 to play a role in boosting the potency of the next generation of CAR-T cell products to enhance adoptive cell therapy for solid tumors without using genetic manipulation."

Data from the studies conducted assessed the potential of PH-894 to improve the quality and potency of HER2-targeted CAR-T cells in a CAR-T expansion model. CAR-T cells were activated with an OKT3 antibody and treated with PH-894. Results showed that PH-894 reduced the expansion-associated production of BRD4 and BRD4-regulated genes and mitigated the production of inhibitory receptors and markers of T cell exhaustion, PD-1, TIGIT and TIM3. Additionally, PH-894 preserved putative T cell stem-cell memory and central memory, phenotypes associated with cell persistence, on HER2-CAR-T cells that were otherwise depleted by cell expansion without the use of PH-894.

Phio’s presentation detailing the data presented at ASGCT (Free ASGCT Whitepaper) titled, "Self-delivering RNAi Targeting BRD4 (PH-894) Improves the Phenotype of HER2-CAR-T Cells During Expansion" will be made available on the "Investors – Events and Presentations" section of the Company’s website (click here).

On May 16, 2022 Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, reported a clinical trial collaboration and supply agreement with Merck (known as MSD outside the US and Canada) (Press release, Athenex, MAY 16, 2022, View Source [SID1234614661]). The agreement applies to the expansion phase of the Phase 1 clinical trial evaluating Athenex’s oral paclitaxel in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) for certain NSCLC patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement will support the expansion phase of the trial to further investigate the preliminary encouraging results of the KX-ORAX-011 Phase 1 clinical trial evaluating Oraxol (encequidar plus oral paclitaxel) in combination with pembrolizumab for certain NSCLC patients. The two companies will form a Joint Development Committee to review the clinical trial results.

"We are keen to collaborate with Merck to further investigate the therapeutic potential of Oraxol plus KEYTRUDA in patients with NSCLC patients who progressed on previous anti-PD1/ anti-PD-L1 therapy or in combination with chemotherapy," said Dr. Rudolf Kwan, Chief Medical Officer of Athenex. "If the preliminary efficacy and safety data can be confirmed, it may lead to a new paradigm in the treatment of certain NSCLC patients."

KX-ORAX-011 is an ongoing Phase 1 trial evaluating Oraxol in combination with pembrolizumab in patients with advanced solid tumors. Following completion of the dose escalation phase, the expansion phase is currently evaluating the combination therapy in patients with NSCLC who progressed on previous anti-PD1/ anti-PD-L1 therapy or in combination with chemotherapy. The NSCLC expansion cohort is actively recruiting and aims to enroll approximately 50 patients.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About Oral Paclitaxel
Athenex’s oral paclitaxel and encequidar ("oral paclitaxel") is in the earlier stages of development for solid malignancies. Encequidar, the cornerstone of Athenex’s Orascovery technology platform, is a highly specific and potent inhibitor of the transport protein called P-glycoprotein (P-gp) in the gastrointestinal (GI) tract. By localizing P-gp inhibitory activity in the GI tract, encequidar improves the absorption of chemotherapeutic agents while limiting the potential for unnecessary P-gp inhibition at other sites in the body. The potency, selectivity, and low absorption of encequidar enables the oral administration of IV chemotherapies.